Absci’s Financial Standing and Future Plans
– Absci reports having $97.7 million in unrestricted cash, cash equivalents, and short-term investments as of December 31, 2023.
– This capital, together with an $86 million oversubscribed public offering, is expected to fund Absci’s operations until the first half of 2027.
– The company plans to utilize the funds for the further development of its Integrated Drug Creation™ platform and drug candidates, starting with ABS-101 targeting TL1A for the treatment of inflammatory bowel disease.
Author’s Take:
Absci’s successful fundraising efforts, backed by significant financial reserves, position the company strongly to advance its innovative drug development platform and promising candidates. With a clear timeline for funding into 2027 and a focus on addressing unmet medical needs like inflammatory bowel disease, Absci is strategically poised for impactful advancements in the biotechnology sector.
Click here for the original article.